QUANTERIX CORP (QTRX)
US74766Q1013 - Common Stock
We assign a fundamental rating of 4 out of 10 to QTRX. QTRX was compared to 59 industry peers in the Life Sciences Tools & Services industry. QTRX has a great financial health rating, but its profitability evaluates not so good. QTRX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year QTRX has reported negative net income.
In the past year QTRX has reported a negative cash flow from operations.
In the past 5 years QTRX always reported negative net income.
In the past 5 years QTRX always reported negative operating cash flow.
1.2 Ratios
QTRX has a Return On Assets of -7.61%. This is comparable to the rest of the industry: QTRX outperforms 50.85% of its industry peers.
Looking at the Return On Equity, with a value of -9.32%, QTRX is in line with its industry, outperforming 55.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.61% | ||
| ROE | -9.32% | ||
| ROIC | N/A |
ROA(3y)-13.79%
ROA(5y)-15.4%
ROE(3y)-16.45%
ROE(5y)-19.27%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 57.73%, QTRX is doing good in the industry, outperforming 72.88% of the companies in the same industry.
QTRX's Gross Margin has improved in the last couple of years.
QTRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.73% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.15%
GM growth 5Y3.93%
2. Health
2.1 Basic Checks
QTRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, QTRX has more shares outstanding
Compared to 5 years ago, QTRX has more shares outstanding
QTRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
QTRX has an Altman-Z score of 4.13. This indicates that QTRX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.13, QTRX is in the better half of the industry, outperforming 69.49% of the companies in the same industry.
QTRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.13 |
ROIC/WACCN/A
WACC12.19%
2.3 Liquidity
QTRX has a Current Ratio of 9.84. This indicates that QTRX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of QTRX (9.84) is better than 89.83% of its industry peers.
QTRX has a Quick Ratio of 9.26. This indicates that QTRX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 9.26, QTRX belongs to the best of the industry, outperforming 89.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.84 | ||
| Quick Ratio | 9.26 |
3. Growth
3.1 Past
QTRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.05%, which is quite impressive.
QTRX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.97%.
Measured over the past years, QTRX shows a very strong growth in Revenue. The Revenue has been growing by 26.62% on average per year.
EPS 1Y (TTM)67.05%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q34%
Revenue 1Y (TTM)15.97%
Revenue growth 3Y12.3%
Revenue growth 5Y26.62%
Revenue growth Q2Q22.19%
3.2 Future
The Earnings Per Share is expected to decrease by -2.84% on average over the next years.
QTRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.32% yearly.
EPS Next Y-19.2%
EPS Next 2Y-3.32%
EPS Next 3Y9.26%
EPS Next 5Y-2.84%
Revenue Next Year17.44%
Revenue Next 2Y17.64%
Revenue Next 3Y18.6%
Revenue Next 5Y18.32%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for QTRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QTRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.32%
EPS Next 3Y9.26%
5. Dividend
5.1 Amount
QTRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
QUANTERIX CORP
NASDAQ:QTRX (4/25/2024, 3:30:01 PM)
After market: 15.59 0 (0%)15.59
-0.45 (-2.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap593.36M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.61% | ||
| ROE | -9.32% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.73% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.84 | ||
| Quick Ratio | 9.26 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)67.05%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-19.2%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)15.97%
Revenue growth 3Y12.3%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y